00656.HK --


Fosun is fully dedicated to the whole industry chain of pharmaceuticals and healthcare. With an aim to create a one-stop health service ecosystem covering the full life-cycle of families, Fosun is engaged in pharmaceutical research and development, medical devices and diagnosis, medicine distribution, medical services, maternal and child supplies, care services for the elderly and health consumer goods.
  • 4 billion+

    Annual investment in research
    and development of Fosun Pharma

  • 01

    HLX01 (Rituximab Injection),
    the first domestic biosimilar approved in China

  • ~2300

    R&D personnel number

  • ~9000

    Retail pharmacies in China

  • 4,600+

    Approved beds in member hospitals

  • 30 million+

    Patients with severe malaria cured
    with the self-developed artesunate for injection

  • 01

    Foshan Chancheng Central Hospital ranked the
    1st in competitiveness among domestic private hospitals

  • 100 million+

    Monthly average active
    Babytree users